Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 31.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 183,941 shares of the biopharmaceutical company’s stock after purchasing an additional 43,614 shares during the period. Mutual of America Capital Management LLC owned approximately 0.14% of Halozyme Therapeutics worth $9,631,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Dimensional Fund Advisors LP boosted its position in Halozyme Therapeutics by 12.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company’s stock worth $99,363,000 after purchasing an additional 209,530 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in Halozyme Therapeutics by 4.9% during the second quarter. Envestnet Asset Management Inc. now owns 229,620 shares of the biopharmaceutical company’s stock worth $12,023,000 after purchasing an additional 10,651 shares in the last quarter. O Neil Global Advisors Inc. purchased a new position in Halozyme Therapeutics during the second quarter worth approximately $249,000. Federated Hermes Inc. boosted its position in Halozyme Therapeutics by 37.8% during the second quarter. Federated Hermes Inc. now owns 696,131 shares of the biopharmaceutical company’s stock worth $36,449,000 after purchasing an additional 191,030 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its position in Halozyme Therapeutics by 4.6% during the second quarter. DekaBank Deutsche Girozentrale now owns 57,453 shares of the biopharmaceutical company’s stock worth $2,963,000 after purchasing an additional 2,546 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $51.93, for a total value of $519,300.00. Following the sale, the chief financial officer now owns 15,480 shares of the company’s stock, valued at approximately $803,876.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Matthew L. Posard sold 9,881 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total transaction of $570,133.70. Following the sale, the director now owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Nicole Labrosse sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $51.93, for a total value of $519,300.00. Following the sale, the chief financial officer now directly owns 15,480 shares in the company, valued at approximately $803,876.40. The disclosure for this sale can be found here. Insiders have sold 84,881 shares of company stock worth $4,888,184 in the last quarter. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Up 0.6 %

Shares of NASDAQ HALO opened at $62.31 on Thursday. The company has a market capitalization of $7.93 billion, a price-to-earnings ratio of 25.75, a price-to-earnings-growth ratio of 0.57 and a beta of 1.28. The company has a debt-to-equity ratio of 5.19, a current ratio of 7.41 and a quick ratio of 6.21. The business has a 50-day moving average of $58.14 and a two-hundred day moving average of $48.95. Halozyme Therapeutics, Inc. has a 1 year low of $32.83 and a 1 year high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The business had revenue of $231.40 million for the quarter, compared to analysts’ expectations of $204.94 million. During the same quarter in the previous year, the firm earned $0.68 earnings per share. The business’s revenue was up 4.7% compared to the same quarter last year. On average, analysts forecast that Halozyme Therapeutics, Inc. will post 3.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Wells Fargo & Company increased their target price on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, June 7th. Piper Sandler cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their target price for the company from $48.00 to $51.00 in a report on Friday, June 7th. JPMorgan Chase & Co. reduced their target price on Halozyme Therapeutics from $53.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Benchmark reissued a “buy” rating and set a $60.00 target price on shares of Halozyme Therapeutics in a report on Thursday, August 8th. Finally, Morgan Stanley increased their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $59.44.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.